In Canada, 1.3 million seniors take five or more medications, and in complex care 80% of patients are concurrently treated with three or more medications [64].
Patients with CM often travel from physician to physician and center to center, and are prescribed long lists of powerful medications, many in complex combinations that both compromise function and impose risk.
Patients in long-term care frequently have multiple diseases resulting in complex medication regimens, which makes assessment of the risks versus benefits of treatments often difficult.
In complex medication regimens involving agents that induce or inhibit cytochrome P450 enzmyes, consultation with a clinical pharmacist or pharmacologist may be helpful in predicting and/or preventing potentially harmful interactions.
Clinicians need to be aware of potential cytochrome P450 interactions, and in complex medication regimens, consultation with a clinical pharmacist or pharmacologist may be helpful in predicting and/or preventing potentially harmful interactions.
Many patients require more than one IOP-lowering drug [ 5] resulting in complex medication regimens that may be difficult to maintain and that can lead to non-compliance [ 6].
Because those patients need to take multiple medications in a day, the complex regimen often affects the patients' adherence to the treatments.
Patients were categorized as using the following: no insulin (oral diabetes medications only, including biguanides, sulfonylureas, or thiazolidinediones); basal (long-acting) insulin in addition to any oral medications; or complex insulin regimens in addition to any oral medications.
Using data from a published randomized trial (16), we sought to evaluate the effect of a GMC intervention among patients with poorly controlled type 2 diabetes who at study baseline were prescribed no insulin (oral diabetes medications only), basal insulin only (in addition to any oral medications), or complex insulin regimens (in addition to any oral medications).
To asses possible effects of antidepressant medications on complex I subunits in depressed subjects, we divided the depressed group into 2 subgroups: subjects medicated with antidepressant drugs (n = 9) and unmedicated (n = 6) subjects (two of them treated with other psychotropic drugs).
